Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > Recombination

<< Previous

Bullboard Posts

Next >>

Comment by wizzdumbon Mar 28, 2022 10:43am

103 Views

Post# 34551836

RE:Recombination

COVID not going away by any means.

Regular testing for other infections increasing.

Huge increase in capacity about to be unlocked.

Fully funded with largest cash balance in its history and increasing margins.

No exposure to consumer indebtedness or interest rate increases.

Nothing but positives ahead. Second quarter just about to close, likely another record, and AGM on Wednesday. Should start to see NRs announcing new QAPs and VTM customers to fill the expanded capacity soon, it's been so quiet i expect a flurry of announcements in the next 1-3 months. KRC estimate of $2.05 is conservative and Kinlytic agreement is still a wildcard. The fun really starts in Q4 but the cheapy shares will be gone by then.